Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3569577 | 1.00 | PTGDR2 (0.46) | PTGDR2PTGS2PTGS1FAAHKCNH2 | |
| SCHEMBL3572900 | 0.90 | PTGDR2 (0.50) | PTGDR2PTGS2PTGS1FAAHKCNH2 | |
| SCHEMBL3571345 | 0.90 | PTGDR2 (0.50) | PTGDR2PTGS2PTGS1FAAHKCNH2 | |
| SCHEMBL2772862 | 0.80 | PTGDR2 (0.60) | PTGDR2PTGS2PTGS1FAAHKCNH2 | |
| SCHEMBL2770201 | 0.76 | PTGDR2 (0.75) | PTGDR2CYP2C9AKR1B1 | |
| SCHEMBL2771707 | 0.71 | PTGDR2 (0.36) | PTGDR2PTGS2PTGS1CYP2C9AKR1B1 | |
| SCHEMBL2774269 | 0.70 | PTGDR2 (0.51) | PTGDR2PTGS2CYP2C9 | |
| SCHEMBL2769501 | 0.69 | PTGDR2 (0.64) | PTGDR2 | |
| SCHEMBL3579992 | 0.67 | PTGDR2 (0.48) | PTGDR2 | |
| SCHEMBL3577547 | 0.67 | PTGDR2 (0.65) | PTGDR2CYP2C9AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010034-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| EP-2094266-A1 | CRTH2 ANTAGONISTS | Argenta Discovery Limited (GB) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008074966-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010034-A1 | CRTH2 ANTAGONISTS | HRH2, MDH2, HRH1 | PTGDR2 167/4885PTGS2 426/4885PTGS1 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.